However, suitability of T-cell CD74 as a potential biomarker for disease progression in COVID-19 and its relevance in other inflammatory or malignant diseases accompanied by broad T-cell activation still needs to be evaluated in future prospective trials. This evidence concerns the gene CD74 and COVID-19.